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OBJECTIVE — The purpose of this study was to investigate the role of circulating resistin
levels in the development of type 2 diabetes using two prospective cohorts of well-characterized
men and women.
RESEARCH DESIGN AND METHODS — We conducted two prospective case-control
studies nested in the Women’s Health Study (WHS) and Physicians’ Health Study II (PHS II). In
the WHS, during a median of 10-years of follow-up, 359 postmenopausal women, who were
apparently healthy at baseline and later developed type 2 diabetes, were prospectively matched
with 359 healthy control subjects. In the PHS II, with 8 years of total follow-up, 170 men, who
were apparently healthy at baseline and later developed type 2 diabetes, were matched with 170
healthy control subjects. Control subjects were matched by age, race, and time of blood draw.
RESULTS — Resistin levels at baseline were signiﬁcantly higher in women than in men (P 
0.003) and in case patients than in control subjects for both women (P  0.001) and men (P 
0.07). After adjustment for matching factors, physical activity, alcohol intake, smoking, and
family history of diabetes, the relative risk of type 2 diabetes comparing the highest to the lowest
quartile of resistin in women was 2.22 ([95% CI 1.32–3.73]; Ptrend  0.002). This association
was attenuated after further adjustment for BMI (1.51 [0.86–2.65]; Ptrend  0.20) or C-reactive
protein (1.18 [0.68–2.07]; Ptrend  0.60). A similar but weaker pattern was observed in men.
CONCLUSIONS — Elevated levels of circulating resistin were signiﬁcantly related to in-
creased risk of type 2 diabetes, which appears to be partially accounted for by adiposity and the
inﬂammatory process.
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R
esistin (also known as adipocyte-
secreted factor), an adipocyte-
derived hormone, may serve as a
critical molecular link between obesity
and insulin resistance (1–3). Obese and
diabetic mice exhibit high levels of resis-
tin. In murine models, functional reduc-
tions in resistin protein (e.g., anti-resistin
antibodies, resistin gene knockouts) have
been demonstrated to improve insulin
sensitivity as well as to decrease blood
glucose (2–4), free fatty acid (2), and tri-
glyceride levels (2). A reduction in the
amount of functional resistin also in-
creases adipocyte differentiation and adi-
pose mass (2), which can be reversed
upon administration of recombinant re-
sistin (4).
In humans, however, the contribu-
tion of resistin to the pathogenesis of type
2 diabetes remains elusive. Plasma resis-
tin levels have been observed to be higher
in diabetic individuals than in apparently
healthy individuals (5–7). In addition,
thiazolidinedione therapy lowered
plasma resistin levels in clinical trials
(8,9). However, the primary source of re-
sistin in rodents is adipocytes, whereas
the major source in humans has been
shown to be macrophages (10,11), sug-
gesting species-speciﬁc physiological ef-
fects. To this end, prospective data are
neededinwell-deﬁnedpopulationstoex-
amine the association of circulating levels
of resistin with the incident diagnosis of
type 2 diabetes.
Therefore, we conducted two case-
control studies nested within two large,
prospective cohorts, the Women’s Health
Study (WHS) and the Physicians’
Health Study II (PHS II), to investigate
the associations of plasma resistin levels
with type 2 diabetes risk in men and
women. We also explored the potential
role of BMI and inﬂammatory markers
on the association between resistin and
type 2 diabetes.
RESEARCH DESIGN AND
METHODS— The WHS is a random-
ized, double-blind, placebo-controlled,
2  2 factorial trial of low-dose aspirin
and vitamin E for the primary prevention
of cardiovascular disease and cancer. The
original study consisted of 39,876 U.S.
female health professionals aged 45
years (mean age 53.9 years at baseline)
who were free of diabetes, cancer (except
nonmelanoma skin cancer), and cardio-
vascular disease at baseline (12,13). Of
the original 39,876 participants, baseline
blood samples were obtained from
28,345 participants (71%). We restricted
our population to 6,574 postmenopausal
women who were not using hormone re-
placement therapy at the time of blood
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incident diabetes during a median fol-
low-up of 10 years (by February 2005)
were matched in a 1:1 ratio to control
subjects by age (within 1 year), duration
of follow-up (within 1 month), race, and
fasting status at time of blood draw (72%
provided fasting blood samples, deﬁned
as10hsincethelastmeal).Onthebasis
of these eligibility criteria, a total of 359
case patients and 359 control subjects
were included in our analyses from the
WHS.
The PHS II is a randomized, double-
blind, placebo-controlled 2  2  2  2
factorial trial of vitamin E, vitamin C,
-carotene, and multivitamins in the pre-
vention of cardiovascular disease and
cancer in 14,641 U.S. male physicians
aged 55 years who were free of cancer
and cardiovascular disease at baseline
(14). Baseline blood samples were ob-
tained from 11,130 (76%) of the 14,641
PHS II participants. For each incident
case occurring during 8 years of follow-
up, one appropriate control subject was
selected at random from men who pro-
vided baseline blood samples at the time
of diagnosis in the case patient. In total,
170 case patients were matched with 170
control subjects by age (within 1 year),
race, duration of follow-up (within 1
month), and time of blood draw.
Written informed consent was ob-
tained from all participants in both the
WHS and PHS II. Both studies were con-
ducted according to the ethics guidelines
of Brigham and Women’s Hospital, Har-
vard Medical School, and the UCLA insti-
tutional review board.
Ascertainment of diabetes
Details regarding ascertainment of inci-
dent type 2 diabetes in our cohorts have
been reported previously (15). After ex-
cludingthosewithdiabetesatbaseline,all
participantswereaskedannuallywhether
andwhentheyhadadiagnosisofdiabetes
since baseline. With use of the diagnostic
criteria of the American Diabetes Associ-
ation, (16), all self-reported cases of type
2 diabetes were conﬁrmed by a supple-
mental questionnaire. In populations of
healthprofessionalssuchastheWHSand
PHS II, self-reported diagnosis of diabe-
tes yields high validity in identifying
true cases. As conﬁrmation, a small val-
idation study was conducted, in which
self-reported diabetes in the WHS was
validated against physician-led tele-
phone interviews, supplementary ques-
tionnaires, and medical record reviews,
all yielding positive predictive values
91% (17).
Laboratory procedures
Blood samples were centrifuged and
stored in liquid nitrogen freezers.
Matched case-control pairs were handled
identically and assayed in random order
in the same analytical run in each cohort.
Laboratory personnel were blinded to
case-control status during all assays. A1C
wasmeasuredusingaFoodandDrugAd-
ministration–andU.S.NationalGlycohe-
moglobin Standardization Program–
approved immunoassay (Hitachi 911;
Roche Diagnostics), as described previ-
ously (18). Plasma levels of resistin were
measured by ELISA (ALPCO Diagnostics,
Windham, NH). The assay has a sensitiv-
ity of 0.2 ng/ml and day-to-day variabili-
ties of the assay at concentrations of 8.95
and 13.08 ng/ml are 8.9 and 7.4%, re-
spectively. Tumor necrosis factor- re-
ceptor II (TNF-RII) was also measured by
ELISA (R&D Systems). The day-to-day
variabilities of the assay at concentrations
of 89.9, 197.0, and 444.0 pg/ml are 5.1,
3.5, and 3.6%, respectively. As described
previously (19), C-reactive protein (CRP)
(performedintheWHSonly)wasassayed
using validated methods at a certiﬁed lab-
oratory; the average intra-assay coefﬁ-
cient of variation for CRP was 7.8% and
the inter-assay coefﬁcients of variations
were 2.5 and 5.1%.
Statistical analysis
Biomarker values were log-transformed
in all analyses to enhance compliance
with normality assumptions. Baseline
characteristics between case patients and
matched control subjects were compared
using McNemar’s 
2 test for categorical
variablesandapairedttestforcontinuous
variables. Age- and/or BMI-adjusted par-
tial correlation coefﬁcients were esti-
mated to evaluate associations between
plasma resistin levels and traditional met-
abolic risk factors among control sub-
jects. We reported regression estimates
after multiple imputation of missing val-
ues using the ICE and MIM procedures in
STATA 10.0. Variables with the largest
number of missing variables were BMI
(n  12) and multivitamin use (n  11).
To assess the resistin–type 2 diabetes
association, we analyzed the WHS and
PHS II data sets separately using condi-
tional logistic regression with robust vari-
ance estimators. The levels of resistin
were categorized into quartiles based on
their distributions among control sub-
jects. Conditional logistic regression was
applied to estimate the odds ratio (OR)
and 95% CI for type 2 diabetes risk in
each quartile using the lowest quartile as
the referent category. Because risk set
sampling was used for our matched case-
control pairs, the ORs yielded unbiased
estimates of the relative risk (RR), specif-
ically, the rate ratio. Tests of linear trends
across increasing quartiles of resistin lev-
els were conducted by assigning the me-
dian values within quartiles treated as a
continuous variable. We also estimated
the RR per 1 SD increase in log-
transformed resistin levels, assuming a
linear relationship. The following models
were prespeciﬁed in this analysis. The ba-
sic model (model 1) was adjusted for
matching factors (age, ethnicity, and fast-
ing status at time of blood draw). The full
model (model 2) was further adjusted for
established type 2 diabetes risk factors of
smoking (current or former/never), alco-
hol use (3 drinks/month, 1–6 drinks/
week, or 1 drink/day), physical activity
(1, 1–3, or 4 times/week), and family
history of diabetes in a ﬁrst-degree rela-
tive (yes/no). In model 3, we additionally
adjusted for BMI (continuous) in the full
model to assess the impact of BMI on the
resistin–type 2 diabetes association. In
model 4, we further adjusted the full
model for CRP, but because CRP was not
available in the PHS II data set, we ad-
justed the full model for TNF-RII in the
PHS II data set as a surrogate marker for
CRP; the Pearson’s correlation between
TNF-RII and CRP was r  0.28 in the
WHS data set, consistent with ﬁndings in
other populations. Model 5 was the same
as model 4 with the addition of BMI as a
covariate.
Because there was insufﬁcient statis-
tical evidence to suggest that the resistin–
type 2 diabetes association differed by
sex, we subsequently performed sub-
group analyses in the pooled data set to ex-
aminepotentialeffectmodiﬁcationbylevels
of prespeciﬁed risk factors: sex (male or fe-
male), BMI (normal/underweight, over-
weight, or obese), age (60 or 60
years),familyhistoryofdiabetesinaﬁrst-
degree relative (yes/no), physical activity
(1, 1–3, or 4 times/week), alcohol in-
take (3 drinks/month, 1–6 drinks/
week, or 1 drink/day), smoking status
(nonsmoker, former smoker, or current
smoker), A1C (less than median or more
than or equal to median), and TNF-RII
(lessthanmedianormorethanorequalto
median). The statistical signiﬁcance of
these interactions was tested by using a
Serum resistin and risk of type 2 diabetes
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a 
2 test for homogeneity (for variables
with more than two levels) of the pooled
estimates of the interaction terms.
We performed additional sensitivity
analyses to assess the robustness of our
estimates. First, we conducted a series of
analyses to address the concern that un-
derdiagnosed type 2 diabetes may have
biased our ﬁndings. In one analysis we
excluded diabetes case patients (and their
matched control subjects) in whom dia-
betes was diagnosed within the ﬁrst 3
years of follow-up (154 women and 148
menexcluded).Inanotheranalysisweex-
cluded case patients who had elevated
risks of developing type 2 diabetes at
baseline(deﬁnedbyA1C6.5%andBMI
30 kg/m
2 at baseline) (462 women and
172 men excluded). Second, we evalu-
ated the inﬂuence of adjusting for A1C in
our estimates. Third, because CRP was
only measured in the WHS, we assessed
the inﬂuence of adjusting for another in-
ﬂammatorymarker(aloneandwithBMI),
TNF-RII, which was measured in both
data sets. Last, we assessed the inﬂuence
of using a different measure of adiposity
by adjusting for waist circumference (in-
stead of BMI); however, waist circumfer-
ence was only measured in the WHS and
was collected 72 months after baseline.
Thus, we adjusted for waist circumfer-
ence in the WHS, adjusted for BMI in the
PHSII,andpooledtheestimates.Allanal-
yses were conducted using Stata 10.0
(StataCorp, College Station, TX).
RESULTS— Compared with control
subjects, patients with incident cases of
type 2 diabetes had a greater proportion
of traditional risk factors at baseline (Ta-
ble 1). In both men and postmenopausal
women, case patients had higher values
than control subjects for BMI, proportion
with a family history of diabetes, TNF-RII
(and CRP, but only measured in women),
A1C, and resistin levels. Interestingly, re-
sistin levels were signiﬁcantly higher in
women than in men (geometric mean
11.89  1.81 vs. 10.27  1.87 ng/ml,
respectively; P  0.003).
Correlation coefﬁcients between re-
sistin levels and several metabolic mea-
sures are displayed in Table 2. BMI was
poorly correlated with plasma resistin in
men(r0.08,P0.30)andmoderately
correlated in women (r  0.26, P 
0.001). The strongest correlations were
between resistin and inﬂammatory mark-
ers (TNF-RII and/or CRP), which re-
mained positive even after adjustment for
age and BMI (TNF-RII in PHS II: r  0.29,
P0.001;TNF-RIIinWHS:r0.28,P
0.001; and CRP in WHS: r  0.19, P 
0.001).
Inwomen,theriskofdevelopingtype
2 diabetes among participants catego-
rized in the highest quartile of plasma re-
sistin was signiﬁcantly higher than that of
participants in the lowest quartile (RR
2.35[95%CI1.50–3.69];Ptrend0.001)
aftercontrollingonlyformatchingfactors
(Table 3). This association was similar af-
ter additional controls for traditional dia-
betesriskfactorswereadded(2.22[1.32–
3.73], Ptrend  0.002). However, further
adjustment for BMI dramatically attenu-
ated the association (1.51 [0.86–2.65],
Ptrend0.20).Theadditionaladjustment
for inﬂammatory markers led to an even
greater attenuation of the association.
In men, after controlling only for
matching factors, there was a trend to-
ward a positive association between resis-
tinlevelsandtype2diabetesrisk(RR1.53
[95% CI 0.82–2.85], Ptrend  0.09, com-
paring the highest with the lowest quar-
tiles), although it was not statistically
signiﬁcant (Table 3). This nonsigniﬁcant
association was virtually unchanged after
additional adjustment for traditional dia-
betes risk factors and further attenuated
with the additional adjustment for BMI.
Differences in RRs between men and
womenwerenotstatisticallysigniﬁcantin
any of the models we examined; thus, we
pooled the estimates from both men and
women to increase statistical precision in
the RR estimates. Our subgroup analyses
revealed no substantial evidence for the
presence of signiﬁcant heterogeneity
among the prespeciﬁed type 2 diabetes
risk factor variables that we examined for
potential effect modiﬁcation of the RRs
(see supplemental Table A1, available in
an online appendix at http://cdx.doi.org/
10.2337/dc08-1625).
The sensitivity analyses assessing the
inﬂuence of underdiagnosed cases
showedoveralltrendsthatweresimilarto
our main results (see supplemental Table
Table 1—Baseline characteristics of case patients and control subjects
Women Men
Case
patients
Control
subjects P
Case
patients
Control
subjects P
n 358 358 170 170
Demographics
Age (years) 60.4  6.0 60.3  6.1 (Matched) 63.6  7.5 63.4  7.5 (Matched)
Race (% Caucasian) 92.3 92.9 (Matched) 86.9 85.0 (Matched)
BMI (kg/m
2) 31.0  6.1 26.0  5.0 0.001 28.7  3.9 25.6  3.5 0.001
Lifestyle factors
Alcohol consumption (1 drink/day) 5.2 11.2 0.001 28.8 26.1 0.72
Current smoking (%) 14.7 13.5 0.74 5.9 1.3 0.01
Strenuous physical activity (% 4 times/week) 9.2 10.9 0.26 9.2 11.8 0.38
Current multivitamin use (%) 23.3 25.3 0.52 28.1 25.5 0.90
Medical history
Family history of diabetes (%) 48.3 24.1 0.001 36.6 19.0 0.01
Biological markers*
Resistin (ng/ml) 13.0  1.9 10.8  1.7 0.001 10.9  2.0 9.6  1.8 0.07
TNF-IIR (pg/ml) 2,811  1.3 2,671  1.3 0.009 2,300  1.3 2,229  1.2 0.19
A1C (%) 5.7  1.2 5.1  1.1 0.001 6.1  1.2 5.2  1.1 0.001
Data are means  SD unless indicated otherwise. Paired t test was used to calculate P values of continuous variables between case patients and control subjects; for
categorical variables, McNemar’s test was used to test for differences between case patients and control subjects. *Geometric means are displayed.
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A1C strengthened the association be-
tween resistin and type 2 diabetes, al-
though some of the estimates were
unstable because of the small sample size.
Adjusting for TNF-RII in both data sets
attenuated the association between resis-
tin and type 2 diabetes but not to the ex-
tentobservedwhenCRPwasusedinstead
of TNF-RII in the WHS; nonetheless, the
linear trend remained signiﬁcant (P 
0.01). Further adjustment for BMI with
TNF-RII did not alter estimates substan-
tially. Furthermore, adjusting for waist
circumference (in the WHS) instead of
BMI also did not alter the estimates sub-
stantially.
CONCLUSIONS— Inthesetwopro-
spective nested case-control studies of
middle-aged men and postmenopausal
women,elevatedbaselinelevelsofresistin
were associated with an increased risk of
type 2 diabetes, which was attenuated by
adjustment for BMI and/or inﬂammatory
markers. Also, there was no signiﬁcant
modiﬁcation by sex, BMI categories, age,
family history of diabetes, physical activ-
ity, alcohol consumption, or cigarette
smoking status at baseline. The present
analysis differed from previous studies,
which were predominantly cross-sectional,
because it was prospective with several
years of follow-up, was adjusted for mul-
tiple covariates, and had a relatively large
sample size.
In a large, prospectively ascertained
cohort, Heidemann et al. (20) used a sim-
ilar design in 2,274 female nurses and
found results nearly identical to ours: a
strong association between resistin and
risk of diabetes that was attenuated after
further adjustment for BMI. Despite the
consistency of these ﬁndings, further in-
vestigation is needed to reveal the mech-
anisms underlying the interrelationship
among adiposity, resistin, and type 2
diabetes.
Our data are consistent with the pos-
itivecorrelationbetweenBMIandresistin
levelsreportedpreviously(5,6).Despitea
nonsigniﬁcant linear correlation among
men, there was some evidence of a posi-
tive correlation between resistin levels
andBMIamongtheoverweightandobese
control subjects (r
2  0.11, P  0.04).
However, ﬁndings from previous studies
have not been entirely consistent either,
as numerous studies showed no signiﬁ-
cant correlations (7,21) between adiposity
and resistin levels. These null ﬁndings
could be due to the method with which ad-
iposity was measured. In our sensitivity
analyses, adjusting for waist circumference
(albeit, measured 72 months after baseline)
Table 2—Partial correlation coefﬁcients of plasma resistin levels with baseline metabolic
parameters among men and women control subjects adjusted for age and/or BMI
Metabolic factors
Correlation coefﬁcients
Age-adjusted Age- and BMI-adjusted
rPrP
Men (n  170)
BMI 0.08 0.30 — —
TNF-RII 0.29 0.001 0.29 0.001
A1C 0.11 0.15 0.10 0.20
Systolic blood pressure 	0.05 0.52 	0.07 0.37
Diastolic blood pressure 	0.06 0.42 	0.06 0.45
BMI 0.26 0.001 — —
Women (n  358)
Waist circumference 0.20 0.001 0.02 0.66
TNF-RII 0.33 0.001 0.28 0.001
CRP 0.28 0.001 0.19 0.001
A1C 0.09 0.11 0.07 0.22
Cholesterol 0.08 0.12 0.04 0.50
HDL cholesterol 	0.13 0.02 	0.05 0.32
LDL cholesterol 0.10 0.07 0.06 0.24
Triglycerides 0.13 0.01 0.07 0.17
Systolic blood pressure 0.13 0.02 0.04 0.41
Diastolic blood pressure 0.10 0.07 0.02 0.70
Table 3—RR estimates for developing type 2 diabetes by circulating levels of resistin in men and women, separately
Variable Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend
Continuous
(per 1 SD increase)*
Women (case patients/control subjects) 56/90 87/88 88/91 127/89
Basic model† 1.00 1.63 (1.03–2.58) 1.60 (1.01–2.52) 2.35 (1.50–3.69) 0.001 1.37 (1.17–1.59)
Full model‡ 1.00 1.38 (0.84–2.27) 1.40 (0.84–2.35) 2.22 (1.32–3.73) 0.002 1.36 (1.14–1.61)
Full model 
 BMI 1.00 1.43 (0.85–2.40) 1.36 (0.81–2.30) 1.51 (0.86–2.65) 0.20 1.17 (0.98–1.39)
Full model 
 CRP§ 1.00 1.12 (0.64–1.95) 1.03 (0.60–1.76) 1.18 (0.68–2.07) 0.60 1.10 (0.92–1.32)
Full model 
 BMI 
 CRP§ 1.00 1.24 (0.72–2.16) 1.13 (0.66–1.95) 1.13 (0.63–2.01) 0.85 1.07 (0.89–1.28)
Men (case patients/control subjects) 54/59 26/45 38/28 52/38
Basic model† 1.00 0.76 (0.39–1.51) 1.01 (0.54–1.87) 1.53 (0.82–2.85) 0.09 1.21 (0.98–1.48)
Full model‡ 1.00 0.73 (0.34–1.53) 1.10 (0.57–2.12) 1.51 (0.75–3.02) 0.13 1.23 (0.99–1.53)
Full model 
 BMI 1.00 0.53 (0.23–1.22) 0.80 (0.35–1.86) 1.19 (0.54–2.62) 0.38 1.19 (0.91–1.56)
Full model 
 TNF-RII§ 1.00 0.71 (0.33–1.51) 1.06 (0.54–2.06) 1.42 (0.68–2.98) 0.18 1.22 (0.97–1.53)
Full model 
 BMI 
 TNF-RII§ 1.00 0.56 (0.24–1.32) 0.93 (0.38–2.28) 1.39 (0.56–3.46) 0.26 1.26 (0.94–1.71)
Data are RR (95% CI). *RR per 1 SD increase in log-transformed values of resistin. †Basic model adjusted for matching factors (i.e., age, ethnicity, and fasting status
at time of blood draw). ‡Full model adjusted for matching factors and diabetes risk factors (i.e., alcohol intake, exercise, cigarette smoking status, and family history
of diabetes). §As an inﬂammatory marker, TNF-RII was adjusted in the PHS II because the CRP measure was not available.
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not change the estimates substantially.
Cell-culture experiments on isolated
monocytes demonstrated that resistin
regulates proinﬂammatory cytokine se-
cretion through the nuclear factor-B
pathway (22), a master controller of the
proinﬂammatoryprocess.Also,thehighest
levels of resistin mRNA (10) and protein
(23) were found in human mononuclear
cells (e.g., macrophages), a major source of
proinﬂammatory markers. Macrophage
inﬁltration into adipose tissue is a major
feature of obesity (24). Furthermore, our
ﬁndings that adjusting for inﬂammatory
biomarkers attenuated the magnitude of
association between plasma resistin levels
and type 2 diabetes support the notion
that the role of resistin inthedevelopment
of type 2 diabetes is mediated through the
inﬂammatory pathway. However, speciﬁc
regulationandeffectorsofresistinaswellas
different effects between plasma and tissue-
level resistin remain to be clariﬁed.
Several limitations need to be con-
sidered when interpreting our ﬁndings.
First, positive associations that were of
borderline statistical signiﬁcance may
have been due to insufﬁcient sample
size. However, we did observe similar
trends for the positive associations of
resistin with risk of type 2 diabetes in
bothmenandwomen.Endpointmisclas-
siﬁcation may be a concern because the
study populations were not screened for
glucose intolerance, and the diagnosis
was self-reported. However, all partici-
pants in this study were health profes-
sionals, who have been shown to have
more robust and valid self-reported diag-
nostic information and a relatively high
screening rate (25). Moreover, our sensi-
tivity analyses showed consistent trends
for the relation of resistin and type 2 dia-
betes even after the exclusion of all cases
occurring in the ﬁrst 3 years of follow-up
orexclusionofparticipantswithhighBMI
and A1C levels at baseline.
Insummary,ourprospectivestudyof
two well-characterized cohorts of men
and women indicate that elevated levels
of circulating resistin were signiﬁcantly
related to an increased risk of type 2
diabetes and that the potential effects of
resistin on diabetes risk were attenuat-
ed after adjustment for adiposity and
inﬂammation.
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